Peterson Bianca, Weyers Morné, Steenekamp Jan H, Steyn Johan D, Gouws Chrisna, Hamman Josias H
Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), North-West University, Potchefstroom 2520, South Africa.
Pharmaceutics. 2019 Jan 16;11(1):33. doi: 10.3390/pharmaceutics11010033.
Many new chemical entities are discovered with high therapeutic potential, however, many of these compounds exhibit unfavorable pharmacokinetic properties due to poor solubility and/or poor membrane permeation characteristics. The latter is mainly due to the lipid-like barrier imposed by epithelial mucosal layers, which have to be crossed by drug molecules in order to exert a therapeutic effect. Another barrier is the pre-systemic metabolic degradation of drug molecules, mainly by cytochrome P450 enzymes located in the intestinal enterocytes and liver hepatocytes. Although the nasal, buccal and pulmonary routes of administration avoid the first-pass effect, they are still dependent on absorption of drug molecules across the mucosal surfaces to achieve systemic drug delivery. Bioenhancers (drug absorption enhancers of natural origin) have been identified that can increase the quantity of unchanged drug that appears in the systemic blood circulation by means of modulating membrane permeation and/or pre-systemic metabolism. The aim of this paper is to provide an overview of natural bioenhancers and their main mechanisms of action for the nasal, buccal, pulmonary and oral routes of drug administration. Poorly bioavailable drugs such as large, hydrophilic therapeutics are often administered by injections. Bioenhancers may potentially be used to benefit patients by making systemic delivery of these poorly bioavailable drugs possible via alternative routes of administration (i.e., oral, nasal, buccal or pulmonary routes of administration) and may also reduce dosages of small molecular drugs and thereby reduce treatment costs.
许多具有高治疗潜力的新化学实体被发现,然而,这些化合物中的许多由于溶解度差和/或膜渗透特性不佳而表现出不良的药代动力学性质。后者主要是由于上皮粘膜层形成的类脂屏障,药物分子必须穿过该屏障才能发挥治疗作用。另一个屏障是药物分子的系统前代谢降解,主要由位于肠道肠细胞和肝脏肝细胞中的细胞色素P450酶进行。尽管鼻内、颊部和肺部给药途径避免了首过效应,但它们仍然依赖药物分子跨粘膜表面的吸收来实现全身给药。已鉴定出生物增强剂(天然来源的药物吸收增强剂),其可通过调节膜渗透和/或系统前代谢来增加全身血液循环中出现的未改变药物的量。本文的目的是概述天然生物增强剂及其在鼻内、颊部、肺部和口服给药途径中的主要作用机制。生物利用度差的药物,如大分子亲水性治疗药物,通常通过注射给药。生物增强剂有可能通过替代给药途径(即口服、鼻内、颊部或肺部给药途径)实现这些生物利用度差的药物的全身给药,从而使患者受益,还可能降低小分子药物的剂量,从而降低治疗成本。